COVID-19: Learn the precautions Scripps is taking for safe, in-person visitsĀ Learn more

Investigational Drug for Aspirin Exacerbated Respiratory Disease (AERD)

COVID-19 update:

In response to the COVID pandemic, Scripps Health has temporarily suspended enrollment for all clinical trials. Exceptions will exist for trials with curative intent, life-saving treatment or when no standard of care exists. For questions, please call Scripps Office for the Protection of Research Subjects at 858-678-6402.

Trial ID:
Andrew A. White, M.D.
This study will compare the investigational drug ifetroban to a placebo for improving symptoms and quality of life in patients with AERD. Participants will receive study drug or placebo once daily for up to 8 weeks, and will have a telephone visit at week 1 with additional clinic follow-up visits at 4, 8, and 10 weeks.

Inclusion Criteria

  • Have a history of physician-diagnosed asthma
  • Have a history of at least two reactions to oral aspirin
  • Be at least 18 years of age or older
  • Active AERD symptoms within two weeks of starting treatment

Exclusion Criteria

  • Be a current smoker or have used tobacco within the last three months
  • Have participated in a clinical trial with ifetroban within the past three months.

Additional Info

  • Participants will also be asked to donate nasal fluid, blood and urine specimens to be stored and used for future research on AERD.

Contact Info:

  • heather catchpole